Hanno Riess

Summary

Affiliation: Humboldt University
Country: Germany

Publications

  1. ncbi Hyperthermia in combined treatment of cancer
    P Wust
    Department of Radiation Oncology, Charite Medical School, Campus Virchow Klinikum, Berlin, Germany
    Lancet Oncol 3:487-97. 2002
  2. ncbi Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer - a subgroup analysis of CERTIFY
    Sylvia Haas
    Institut für Experimentelle Onkologie und Therapieforschung, Technische Universitat Munchen, Germany
    BMC Cancer 11:316. 2011
  3. ncbi Intraluminal instillation of urokinase and autologous plasma: a method to unblock occluded central venous ports
    Georg Seifert
    Department of Paediatric Oncology Haematology, Charite Universitatsmedizin Berlin, Germany
    BMC Cancer 6:103. 2006
  4. ncbi Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy)
    Hanno Riess
    Charite Campus Virchow Clinic, Medical Clinic Hematology Oncology, Augustenburger Platz 1, 13353 Berlin, Germany
    BMC Cancer 8:361. 2008
  5. ncbi [Secondary osteoporosis induced by anticoagulants?]
    H Riess
    Medizinische Klinik und Poliklinik mit Schwerpunkt Hämatologie und Onkologie, Charite, Campus Virchow Klinikum, Medizinische Fakultat, Humboldt Universitat, Augustenburger Platz 1, 13353 Berlin
    Orthopade 30:451-5. 2001
  6. ncbi A randomized, double-blind study of certoparin vs. unfractionated heparin to prevent venous thromboembolic events in acutely ill, non-surgical patients: CERTIFY Study
    H Riess
    Charite, Campus Virchow Klinikum, Berlin, Germany
    J Thromb Haemost 8:1209-15. 2010
  7. ncbi Fixed-dose, body weight-independent subcutaneous low molecular weight heparin Certoparin compared with adjusted-dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis
    Hanno Riess
    Medical Clinic, Charite University Clinic, Campus Virchow Clinic, Berlin, Germany
    Thromb Haemost 90:252-9. 2003
  8. ncbi Salvage therapy for relapsed posttransplant lymphoproliferative disorders (PTLD) with a second progression of PTLD after Upfront chemotherapy: the role of single-agent rituximab
    Ralf U Trappe
    Department of Hematology and Oncology, Charite Universitatsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany
    Transplantation 84:1708-12. 2007
  9. ncbi Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab
    Ralf Trappe
    1Department of Hematology and Oncology, Charite Universitatsmedizin Berlin, Berlin, Germany
    Transplantation 83:912-8. 2007
  10. ncbi Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group
    Uwe Pelzer
    Universitatsmedizin Berlin Charite, Centrum für Tumormedizin, Augustenburger Platz 1, 13353 Berlin, Germany
    Eur J Cancer 47:1676-81. 2011

Detail Information

Publications95

  1. ncbi Hyperthermia in combined treatment of cancer
    P Wust
    Department of Radiation Oncology, Charite Medical School, Campus Virchow Klinikum, Berlin, Germany
    Lancet Oncol 3:487-97. 2002
    ..However, for every particular temperature-dependent interaction exploited for clinical purposes, sophisticated control of temperature, spatially as well as temporally, in deep body regions will further improve the potential...
  2. ncbi Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer - a subgroup analysis of CERTIFY
    Sylvia Haas
    Institut für Experimentelle Onkologie und Therapieforschung, Technische Universitat Munchen, Germany
    BMC Cancer 11:316. 2011
    ..Patients with cancer have an increased risk of VTE. We compared VTE rates and bleeding complications in 1) cancer patients receiving LMWH or UFH and 2) patients with or without cancer...
  3. ncbi Intraluminal instillation of urokinase and autologous plasma: a method to unblock occluded central venous ports
    Georg Seifert
    Department of Paediatric Oncology Haematology, Charite Universitatsmedizin Berlin, Germany
    BMC Cancer 6:103. 2006
    ..Therapeutic use and effective function of recombinant urokinase (r-UK) for occluded ports need the presence of plasminogen...
  4. ncbi Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy)
    Hanno Riess
    Charite Campus Virchow Clinic, Medical Clinic Hematology Oncology, Augustenburger Platz 1, 13353 Berlin, Germany
    BMC Cancer 8:361. 2008
    ..This phase IIb study was designed to analyze the efficacy of enoxaparin in patients with locally advanced or metastatic pancreatic cancer undergoing systemic chemotherapy...
  5. ncbi [Secondary osteoporosis induced by anticoagulants?]
    H Riess
    Medizinische Klinik und Poliklinik mit Schwerpunkt Hämatologie und Onkologie, Charite, Campus Virchow Klinikum, Medizinische Fakultat, Humboldt Universitat, Augustenburger Platz 1, 13353 Berlin
    Orthopade 30:451-5. 2001
    ....
  6. ncbi A randomized, double-blind study of certoparin vs. unfractionated heparin to prevent venous thromboembolic events in acutely ill, non-surgical patients: CERTIFY Study
    H Riess
    Charite, Campus Virchow Klinikum, Berlin, Germany
    J Thromb Haemost 8:1209-15. 2010
    ..unfractionated heparin (UFH) for the prevention of venous thromboembolic events is available. Objectives: To compare the efficacy and safety of certoparin with those of UFH...
  7. ncbi Fixed-dose, body weight-independent subcutaneous low molecular weight heparin Certoparin compared with adjusted-dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis
    Hanno Riess
    Medical Clinic, Charite University Clinic, Campus Virchow Clinic, Berlin, Germany
    Thromb Haemost 90:252-9. 2003
    ..This effect is maintained during a 6-months follow-up of treatment with oral anticoagulation...
  8. ncbi Salvage therapy for relapsed posttransplant lymphoproliferative disorders (PTLD) with a second progression of PTLD after Upfront chemotherapy: the role of single-agent rituximab
    Ralf U Trappe
    Department of Hematology and Oncology, Charite Universitatsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany
    Transplantation 84:1708-12. 2007
    ..Single-agent rituximab salvage therapy is an effective treatment option in this setting of intensively pretreated patients, with virtually no therapy-associated toxicity...
  9. ncbi Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab
    Ralf Trappe
    1Department of Hematology and Oncology, Charite Universitatsmedizin Berlin, Berlin, Germany
    Transplantation 83:912-8. 2007
    ..This retrospective analysis was undertaken to determine the efficacy and safety of salvage therapy in recipients of solid organ transplants with progression of PTLD after rituximab first-line therapy...
  10. ncbi Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group
    Uwe Pelzer
    Universitatsmedizin Berlin Charite, Centrum für Tumormedizin, Augustenburger Platz 1, 13353 Berlin, Germany
    Eur J Cancer 47:1676-81. 2011
    ..We initiated a phase III multicentre study comparing OFF versus best supportive care (BSC) in patients with APC progressing while on gemcitabine therapy...
  11. ncbi Second-line therapy in refractory pancreatic cancer. results of a phase II study
    Uwe Pelzer
    Universitatsmedizin Berlin, CharitéCentrum fur Tumormedizin, Medizinische Klinik m S Hamatologie Onkologie, Berlin, Germany
    Onkologie 32:99-102. 2009
    ....
  12. ncbi Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial
    Ralf Trappe
    Department of Haematology and Oncology, Campus Virchow Klinikum, Charite Universitatsmedizin Berlin, Berlin, Germany
    Lancet Oncol 13:196-206. 2012
    ....
  13. ncbi Interventionally implanted port catheter systems for hepatic arterial infusion of chemotherapy in patients with colorectal liver metastases: a Phase II-study and historical comparison with the surgical approach
    Bert Hildebrandt
    CharitéCentrum fur Tumormedizin, Medizinische Klinik mit Schwerpunkt Hämatologie und Onkologie, Campus Virchow Klinikum, Charite Universitatsmedizin Berlin, Berlin, Germany
    BMC Cancer 7:69. 2007
    ....
  14. ncbi First-line treatment of pancreatic cancer patients with the combination of 5-fluorouracil/folinic acid plus gemcitabine: a multicenter phase II trial by the CONKO-study group
    Uwe Pelzer
    Charité Centrum für Tumormedizin, Universitatsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany
    Cancer Chemother Pharmacol 68:1173-8. 2011
    ..The study is based on our completed dose finding phase I trial...
  15. ncbi Recurrent hepatocellular carcinoma in liver transplant recipients: parameters affecting time to recurrence, treatment options and survival in the sorafenib era
    Tulio E F Pfiffer
    1Department of Hematology, Oncology and Tumor Immunology, Universitatsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany
    Tumori 97:436-41. 2011
    ..A growing number of patients with hepatocellular carcinoma undergo liver transplantation, but there is little data on recurrence and its treatment in the posttransplant setting...
  16. ncbi Genetic dissection of apoptosis and cell cycle control in response of colorectal cancer treated with preoperative radiochemotherapy
    Isrid Sturm
    University Medical Center Charite, Campus Virchow Klinikum, Department of Hematology and Oncology, 13353 Berlin, Germany
    BMC Cancer 6:124. 2006
    ..e. 5-fluorouracil (5-FU), ionising gamma-radiation (IR) and heat shock/hyperthermia...
  17. ncbi Stress induced changes in lymphocyte subpopulations and associated cytokines during whole body hyperthermia of 41.8-42.2 degrees C
    Olaf Ahlers
    Klinik fur Anasthesiologie und Operative Intensivmedizin, Charite Universitatsmedizin Berlin, Campus Virchow Klinikum, 13344, Berlin, Germany
    Eur J Appl Physiol 95:298-306. 2005
    ..Further studies are necessary to examine the pathophysiological details and to evaluate the meaning of these transient immunological changes for patient's outcome...
  18. ncbi Quantitative analysis of EBV-specific CD4/CD8 T cell numbers, absolute CD4/CD8 T cell numbers and EBV load in solid organ transplant recipients with PLTD
    Kathrin Sebelin Wulf
    Charite Universitaetsmedizin Berlin, Campus Virchow Klinikum, Med Klinik m S Haematologie Onkologie, D 13353 Berlin, Germany
    Transpl Immunol 17:203-10. 2007
    ..Further studies are needed to verify if a low absolute CD4 T cell count presents a risk factor for the development of PTLD in SOT recipients...
  19. ncbi Adjuvant chemotherapy with folinic acid and 5-fluorouracil in patients with locally advanced rectal cancer previously treated by preoperative radiochemotherapy and curative tumor resection
    Bert Hildebrandt
    Medizinische Klinik für Hämatologie und Onkologie, Charite, Campus Virchow Klinikum, Augustenburger Platz 1, 13353 Berlin, Germany
    Int J Colorectal Dis 21:582-9. 2006
    ..The role of postoperative adjuvant chemotherapy in patients with rectal cancer pretreated by preoperative radiochemotherapy (RCT) and curative surgery is still poorly investigated...
  20. ncbi Evidence for genetic susceptibility towards development of posttransplant lymphoproliferative disorder in solid organ recipients
    Nina Babel
    Department of Nephrology, Charite University Medicine Berlin, Campus Virchow Clinic, Berlin, Germany
    Transplantation 84:387-91. 2007
    ....
  21. ncbi Nonresponse to pre-operative chemotherapy does not preclude long-term survival after liver resection in patients with colorectal liver metastases
    Ulf P Neumann
    Department of General, Visceral, and Transplantation Surgery, Universitatsklinikum Charite, Campus Virchow Klinikum, Humboldt Universitat, Berlin, Germany
    Surgery 146:52-9. 2009
    ..The aim of the study was to identify risk factors for poor outcome in patients with pre-operative chemotherapy of CRM...
  22. ncbi Differential gene expression in peripheral blood lymphocytes of cancer patients treated with whole body hyperthermia and chemotherapy: a pilot study
    Bert Hildebrandt
    Medizinische Klinik mit Schwerpunkt Hämatologie und Onkologie, Campus Virchow Klinikum, Charité Universitätsmedizin Berlin der Humboldt Universität, Berlin, Germany
    Int J Hyperthermia 22:625-35. 2006
    ..The aim of this study was to identify genes that become upregulated in peripheral blood lymphocytes (PBLs) of cancer patients during a combined treatment with WBH and chemotherapy by generating complex arrays of cDNA...
  23. ncbi Cetuximab: appraisal of a novel drug against colorectal cancer
    Bert Hildebrandt
    Centrum für Tumormedizin, Medizinische Klinik mit Schwerpunkt Hämatologie und Onkologie, Charite Campus Virchow Klinikum, Berlin, Germany
    Recent Results Cancer Res 176:135-43. 2007
    ....
  24. ncbi Gemcitabine in combination with 5-fluorouracil with or without folinic acid in the treatment of pancreatic cancer
    Helmut Oettle
    Medizinische Klinik und Poliklinik m S Hämatologie und Onkologie, Medizinische Fakultat der Humboldt Universitat zu Berlin, Berlin, Germany
    Cancer 95:912-22. 2002
    ..However, the results of ongoing Phase III studies must be reviewed before a definitive statement can be made regarding the value of this combination in the treatment of pancreatic cancer...
  25. ncbi Hepatic arterial port systems for treatment of liver metastases: factors affecting patency and adverse events
    Jens Ricke
    Department of Radiology, Charite Campus Virchow Klinikum, Humboldt University, Augustenburgerplatz 1, 13353 Berlin, Germany
    J Vasc Interv Radiol 15:825-33. 2004
    ..To assess the outcome of interventional hepatic arterial port placement in a prospective phase II trial...
  26. ncbi Goal-directed therapy of cardiac preload in induced whole-body hyperthermia
    Maria Deja
    Department of Anesthesiology and Critical Care Medicine, Charite Medical Center, Campus Virchow Clinic, Augustenburger Platz 1, 13353 Berlin, Germany
    Chest 128:580-6. 2005
    ..To optimize volume therapy during induced whole-body hyperthermia (WBH) < or = 42.2 degrees C, pulmonary capillary wedge pressure (PCWP) and intrathoracic blood volume index (ITBVI) were compared as goal parameters...
  27. ncbi Influence of neoadjuvant radiochemotherapy combined with hyperthermia on the quality of life in rectum cancer patients
    T Schulze
    Department of Surgery and Surgical Oncology, , Charit, Campus Buch, , Berlin, Germany
    Int J Hyperthermia 22:301-18. 2006
    ..The addition of hyperthermia during the neoadjuvant therapy with the potentially associated inconveniences has no negative effects on QoL...
  28. ncbi Hepatic arterial infusion chemotherapy for liver metastases from gastric cancer: an analysis in Western patients
    Anne Florcken
    Department of Hematology Oncology and Tumorimmunology, Campus Virchow Klinikum, Charite University Medicine Berlin, Berlin, Germany
    Tumori 97:19-24. 2011
    ..Very limited data about hepatic arterial infusion exist in western gastric cancer patients...
  29. ncbi Association of human leukocyte antigen haplotypes with posttransplant lymphoproliferative disease after solid organ transplantation
    Marion Subklewe
    Charite Universitaetsmedizin Berlin, Campus Virchow Klinikum, Med Klinik m S Haematologie Onkologie, Berlin, Germany
    Transplantation 82:1093-100. 2006
    ....
  30. ncbi Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial
    Helmut Oettle
    Department of Medical Oncology and Hematology, Charite School of Medicine, Campus Virchow Klinikum, Berlin, Germany
    JAMA 297:267-77. 2007
    ..The role of adjuvant therapy in resectable pancreatic cancer is still uncertain, and no recommended standard exists...
  31. ncbi [Standards and perspectives in locoregional hyperthermia]
    Bert Hildebrandt
    Medizinische Klinik für Hämatologie und Onkologie, Campus Virchow Klinikum, Charite Universitatsmedizin Berlin, Berlin, Deutschland
    Wien Med Wochenschr 154:148-58. 2004
    ..We here give a critical update on the proven indications of the different locoregional hyperthermia approaches and on the current clinical and technological progress in this field...
  32. ncbi Fusion imaging using a hybrid SPECT-CT camera improves port perfusion scintigraphy for control of hepatic arterial infusion of chemotherapy in colorectal cancer patients
    Timm Denecke
    Campus Virchow Klinikum, Charite Universitatsmedizin Berlin Klinik fur Strahlenheilkunde und PET Zentrum Berlin, Augustenburger Platz 1 Berlin, 13353 Berlin, Germany
    Eur J Nucl Med Mol Imaging 32:1003-10. 2005
    ..The aim of this study was to evaluate port perfusion scintigraphy in colorectal cancer patients using a hybrid SPECT-CT system for control of minimally invasive intra-arterial port systems within the scope of a phase II trial...
  33. ncbi A non-randomised, single-centre comparison of induction chemotherapy followed by radiochemotherapy versus concomitant chemotherapy with hyperfractionated radiotherapy in inoperable head and neck carcinomas
    Reinhold Graf
    Clinic for Radiation Medicine, Charite Medical School, Campus Virchow Klinikum, Augustenburger Platz, 113353 Berlin, Germany
    BMC Cancer 6:30. 2006
    ..The aim of this study was to compare the results of concomitant application of radiochemotherapy for treating locally advanced head-and-neck carcinoma in comparison with the former standard of sequential radiochemotherapy...
  34. ncbi Parenteral nutrition support for patients with pancreatic cancer. Results of a phase II study
    Uwe Pelzer
    Universitatsmedizin Berlin, Charité Centrum für Tumormedizin, CONKO Study Group, Augustenburger Platz 1, Berlin, Germany
    BMC Cancer 10:86. 2010
    ..The positive influence of BIA determinate predictors by additional nutrition is currently under discussion...
  35. ncbi Percutaneous computed tomography-guided high-dose-rate brachytherapy ablation of breast cancer liver metastases: initial experience with 80 lesions
    Federico Collettini
    Department of Diagnostic and Interventional Radiology, Charite, Campus Virchow Klinikum, Augustenburger Platz 1, 13353 Berlin, Germany
    J Vasc Interv Radiol 23:618-26. 2012
    ..To analyze initial experience with computed tomography-guided high-dose-rate brachytherapy (CT-HDRBT) ablation of breast cancer liver metastases (BCLM)...
  36. ncbi Effective use of high-dose chemotherapy and autologous stem cell rescue for relapsed adult Wilms' tumor and a novel alteration in intron 1 of the WT1 gene
    Ralf Ulrich Trappe
    Department of Hematology and Oncology, Charite University Hospital Berlin, Campus Virchow Klinikum, Augustenburger Platz 1, D 13353 Berlin, Germany
    J Pediatr Hematol Oncol 26:820-3. 2004
    ..Both chemotherapy regimens showed moderate treatment-related toxicity. This report is the first that indicates that adult nephroblastoma patients also may carry WT1 germline mutations...
  37. ncbi Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor
    Matthias Holdhoff
    , Campus Virchow, Charit, , Augustenburger Platz 1, 13353 Berlin, Germany
    Blood Cells Mol Dis 34:181-5. 2005
    ..These results suggest that imatinib may have clinical utility as a radiosensitizer in the treatment of human glioblastoma, possibly through disruption of an autocrine PDGF/PDGFR loop...
  38. ncbi Intraoperative fresh-frozen plasma versus human albumin in craniofacial surgery--a pilot study comparing coagulation profiles in infants younger than 12 months
    Bert Hildebrandt
    Medizinische Klinik m S Hämatologie und Onkologie, Campus Virchow Klinikum, Charite Universitatsmedizin Berlin, Augustenburger Platz 1, 13344 Berlin, Germany
    Thromb Haemost 98:172-7. 2007
    ..However, the course of activation markers suggested a similar extent of clotting and fibrinolytic activation with the use of both transfusion regimens, and there were no differences with regard to clinical endpoints...
  39. ncbi [Recent progress in the treatment of colorectal cancer]
    Peter C Thuss-Patience
    Charite Universitatsmedizin Berlin, Campus Virchow Klinikum, Medizinische Klinik mit Schwerpunkt Hämatologie und Onkologie, Berlin
    Med Klin (Munich) 101:114-9. 2006
    ..Considerable progress has been made in the treatment of colorectal cancer. Many new results have been presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in May 2005 at Orlando, FL, USA...
  40. ncbi Cilengitide (EMD 121974) arrests the growth of a heavily pretreated highly vascularised head and neck tumour
    Jan Dirk Raguse
    Klinik fur Mund, Kiefer und Gesichtschirurgie, klinische Navigation und Robotik Plastische Operationen, Charite Universitatsmedizin Berlin, Campus Virchow Klinikum, Augustenburgerplatz 1, 13353 Berlin, Germany
    Oral Oncol 40:228-30. 2004
    ..case demonstrates the clinical efficacy of the antiangiogenetic agent cilengitide, in combination with gemcitabine, in inhibiting rapid growth of highly vascularized tumour and highlights the potential of this new therapeutic agent..
  41. ncbi Impact of overall treatment time on local control of anal cancer treated with radiochemotherapy
    R Graf
    Center of Radiation Medicine, Campus Virchow Clinic, , Humboldt University, Berlin, Germany
    Oncology 65:14-22. 2003
    ....
  42. ncbi IL-6 and IL-10 in post-transplant lymphoproliferative disorders development and maintenance: a longitudinal study of cytokine plasma levels and T-cell subsets in 38 patients undergoing treatment
    Carl Hinrichs
    Department of Nephrology and Intensive Care, Charite Universitatsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany
    Transpl Int 24:892-903. 2011
    ..Although the specificity of these cells is unclear, their increase might correlate with the impaired tumor-specific cytotoxic-T-lymphocyte (CTL)-response in PTLD...
  43. ncbi Resistance to activated protein C caused by factor V Leiden mutation and orthotopic liver transplantation
    Andreas Loew
    Medizinische Klinik mit Schwerpunkt Hämatologie und Onkologie, Charite, Campus Virchow Klinikum, Humboldt Universitat zu Berlin, Germany
    Transplantation 79:1422-7. 2005
    ..Little is known about the role of FV:Q506 in recipients of human liver grafts and the significance of acquired APCR caused by orthotopic liver transplantation (OLT)...
  44. ncbi Multislice computed tomographic angiography for preinterventional planning of port placement for intra-arterial hepatic infusion chemotherapy
    Lukas Lehmkuhl
    Clinic of Radiology, Nuclear Medicine and Radiation Oncology, Charite University Medicine Berlin, Germany
    J Comput Assist Tomogr 31:66-71. 2007
    ..To determine the impact of preinterventional multislice computed tomographic angiography (MSCTA) on the interventional management of patients scheduled for hepatic port placement...
  45. ncbi Severe thrombocytopenia in a patient with metastatic renal cell carcinoma
    Anne Florcken
    Department of Hematology and Oncology, Charite Universitatsmedizin Berlin, Germany
    Onkologie 32:670-2. 2009
    ..Several blood tests were done to identify the cause of the thrombocytopenia...
  46. ncbi The cellular and molecular basis of hyperthermia
    Bert Hildebrandt
    Medical Clinic, Department of Hematology and Oncology, Charite Medical School, Humboldt University, Campus Virchow Clinic, D 13344 Berlin, Germany
    Crit Rev Oncol Hematol 43:33-56. 2002
    ....
  47. ncbi Changes in hepatic blood flow during whole body hyperthermia
    Maria Deja
    Department of Anaesthesiology and Intensive Care Medicine, Charite Universitatsmedizin Berlin, Germany
    Int J Hyperthermia 26:95-100. 2010
    ..The aim of this clinical study was to determine changes in hepatic blood flow during WBH for the treatment of metastatic cancer...
  48. ncbi [Coagulation analysis in transplantation patients]
    A Loew
    Charite Campus Virchow Klinikum, Augustenburgerplatz 1, 13353 Berlin
    Hamostaseologie 27:185-7. 2007
    ..Underlying diseases leading to liver transplantation as well as the actual transplantation must be considered when interpreting the findings...
  49. ncbi Anaesthesiological experiences with whole body hyperthermia
    T Kerner
    Department of Anaesthesiology and Critical Care Medicine, Charite Medical Center, Virchow Hospital, Humboldt University, D 13344 Berlin, Germany
    Int J Hyperthermia 19:1-12. 2003
    ....
  50. ncbi Evaluation of patients with liver metastases from colorectal cancer for locally ablative treatment with laser induced thermotherapy. Impact of PET with 18F-fluorodeoxyglucose on therapeutic decisions
    H Amthauer
    Klinik fur Strahlenheilkunde, Charite Universitatsmedizin, Augustenburger Platz 1, 13353 Berlin, Germany
    Nuklearmedizin 45:177-84. 2006
    ..In this study we determined the value of FDG-PET in comparison to conventional staging procedures...
  51. ncbi Treatment of PTLD with rituximab and CHOP reduces the risk of renal graft impairment after reduction of immunosuppression
    R Trappe
    Department of Hematology, Campus Virchow Klinikum, Charite Universitatsmedizin Berlin, Berlin, Germany
    Am J Transplant 9:2331-7. 2009
    ..The immunosuppressive effect of single agent rituximab may partially compensate the negative impact of IR on the graft function. Thus, it is possible to reduce immunosuppression when using chemotherapy to treat PTLD...
  52. ncbi The role of gemcitabine alone and in combination in the treatment of pancreatic cancer
    H Oettle
    Medizinische Klinik und Poliklinik mS Hämatologie und Onkologie, Medizinische Fakultat der Humboldt Universitat zu Berlin, Germany
    Anticancer Drugs 11:771-86. 2000
    ..The data suggest that gemcitabine in combination with biomodulated 5-FU should be considered the standard palliative treatment to which other new drug combinations or combined modality chemoradiation regimens should be compared...
  53. ncbi [Radiological-guided liver-port implantation: Evaluation, technical approach, interventional procedure and follow up]
    R Puls
    Klinik fur Strahlenheilkunde, Campus Virchow Klinikum, Germany
    Rofo 173:914-9. 2001
    ..Radiological-guided liver-port implantation: Evaluation, technical approach, interventional procedure and follow up...
  54. ncbi Recombinant human erythropoietin in the treatment of head and neck tumour anaemia
    H Oettle
    Charite Campus Virchow Klinikum, Medical Faculty of the Humboldt University in Berlin Germany
    Int J Oral Maxillofac Surg 30:148-55. 2001
    ..Recombinant human erythropoietin administration improves the therapeutic outcome and the patients' prognosis...
  55. ncbi Monitoring arterial blood pressure during whole body hyperthermia
    T Kerner
    Department of Anesthesiology and Critical Care Medicine, Charite Medical Center, Virchow Hospital, Humboldt University, Berlin
    Acta Anaesthesiol Scand 46:561-6. 2002
    ..This investigation was performed to evaluate the agreement of invasive measurements at various sites, and to compare invasive and non-invasive methods of ABP monitoring under conditions of a heat-induced extreme vasodilation...
  56. ncbi A clinical pilot study of fresh frozen plasma versus human albumin in paediatric craniofacial repair
    T Kerner
    Clinic for Anaesthesiology and Intensive Care Medicine, Charité Centrum 07 for Anaesthesiology, OP Management and Intensive Care Medicine, Charite University Hospital, Berlin, Germany
    J Int Med Res 36:171-7. 2008
    ..Volume replacement during pCFS can be safely performed with both applied protocols. Our data do not demonstrate a major advantage for FFP use, but further evaluation is necessary...
  57. ncbi A phase II trial of gemcitabine in combination with 5-fluorouracil (24-hour) and folinic acid in patients with chemonaive advanced pancreatic cancer
    H Oettle
    Medizinische Klinik und Poliklinik m S Hämatologie und Onkologie, Medizinische Fakultat der Humboldt Universitat zu Berlin, Germany
    Ann Oncol 11:1267-72. 2000
    ..The present study was initiated to investigate the efficacy of gemcitabine in combination with 5-FU-FA...
  58. ncbi Whole-body hyperthermia in the scope of von Ardenne's systemic cancer multistep therapy (sCMT) combined with chemotherapy in patients with metastatic colorectal cancer: a phase I/II study
    B Hildebrandt
    Medizinische Klinik für Hämatologie und Onkologie, Universitätklinikum Charité, Berlin, Germany
    Int J Hyperthermia 20:317-33. 2004
    ..The fact that three patients who did not respond to initial chemotherapy achieved a PR after additional sCMT suggests that sCMT may enhance the effect of chemotherapy in patients with colorectal cancer...
  59. ncbi MRI after magnetic drug targeting in patients with advanced solid malignant tumors
    A J Lemke
    Universitatsklinikum Charite, Campus Virchow Klinikum, Medizinische Fakultat der Humboldt Universitat zu Berlin, Klinik fur Strahlenheilkunde, Berlin, Germany
    Eur Radiol 14:1949-55. 2004
    ..MRI is a suitable method to detect magnetite particles, deposited at the tumor site via magnetic drug targeting. MRI is therefore eligible to control the success of MDT and to assess the tumor size after the end of therapy...
  60. ncbi Treatment of locally recurrent rectal cancer with special focus on regional pelvic hyperthermia
    B Hildebrandt
    Medizinische Klinik mit Schwerpunkt Hämatologie und Onkologie, Campus Virchow Klinikum, Charite Universitatsmedizin Berlin, Germany
    Onkologie 27:506-11. 2004
    ..Here we give a short overview on the options available for the treatment of pelvic recurrence of rectal cancer, with special focus on adjunctive regional pelvic radiofrequency hyperthermia...
  61. ncbi Current status of radiant whole-body hyperthermia at temperatures >41.5 degrees C and practical guidelines for the treatment of adults. The German 'Interdisciplinary Working Group on Hyperthermia'
    B Hildebrandt
    Medizinische Klink für Hämatologie und Onkologie, Campus Virchow Klinikum, Charite Universitatsmedizin Berlin, Augustenburger Platz 1, D 13353 Berlin, Germany
    Int J Hyperthermia 21:169-83. 2005
    ..These recommendations may be helpful to ensure the quality of WBH performed at different institutions...
  62. ncbi Phase I study of gemcitabine in combination with cisplatin, 5-fluorouracil and folinic acid in patients with advanced esophageal cancer
    H Oettle
    Medizinische Klinik und Poliklinik mS Hämatologie und Onkologie, Charite, Campus Virchow Klinikum, Medizinische Facultät der Humboldt Universität zu Berlin, Germany
    Anticancer Drugs 13:833-8. 2002
    ....
  63. ncbi Phase I trial of gemcitabine (Gemzar), 24 h infusion 5-fluorouracil and folinic acid in patients with inoperable pancreatic cancer
    H Oettle
    Medizinische Klinik und Poliklinik mS Hämatologie und Onkologie, Medizinische Fakultat der Humboldt Universitat zu Berlin, Germany
    Anticancer Drugs 10:699-704. 1999
    ..The median time to progressive disease was 31 weeks (range 5-50 weeks). A phase 11 trial is underway to further assess the activity of this combination at the recommended dose of 750 mg/m2 5-FU...
  64. ncbi Regional pelvic hyperthermia as an adjunct to chemotherapy (oxaliplatin, folinic acid, 5-fluorouracil) in pre-irradiated patients with locally recurrent rectal cancer: a pilot study
    B Hildebrandt
    Medizinische Klinik mit Schwerpunkt Hämatologie und Onkologie, Campus Virchow Klinikum, Charite Universitatsmedizin Berlin, Augustenburger Platz 1, D 13353 Berlin, Germany
    Int J Hyperthermia 20:359-69. 2004
    ..Overall toxicity was moderate, although hyperthermia may add side-effects to this approach. Results, moreover, suggest a relevant palliative effect in patients with pre-irradiated pelvic recurrence of rectal cancer...
  65. ncbi Feasibility and analysis of thermal parameters for the whole-body-hyperthermia system IRATHERM-2000
    P Wust
    Department of Radiation Medicine, Charite Medical Center, Berlin, Germany
    Int J Hyperthermia 16:325-39. 2000
    ..In the authors' opinion, improved understanding of the mechanisms and crucial parameters underlying whole body hyperthermia, will enable a controllable and tolerable therapy through proficient contribution to equipment and methods...
  66. ncbi Gemcitabine in the treatment of advanced head and neck cancer
    J D Raguse
    Clinic and Policlinic for Oral and Maxillofacial Surgery, Plastic Surgery, Germany
    Clin Oncol (R Coll Radiol) 17:425-9. 2005
    ..Gemcitabine has demonstrated a broad spectrum anti-tumoural effect and a favourable toxicity profile. These attributes prompted us to introduce gemcitabine into the treatment of head-and-neck tumours...
  67. ncbi Intraperitoneal distribution of ultrasound contrast medium imaged with B-mode ultrasound and colour-stimulated acoustic emission imaging
    R Puls
    Institut fur Radiologie, Campus Charite Mitte, Humboldt Universitat, Schumannstrasse 20 21, 10098 Berlin, Germany
    Eur Radiol 13:695-9. 2003
    ..This method is therefore well suited for imaging port catheter systems prior to chemotherapy...
  68. ncbi Platelet activation through triathlon competition in ultra-endurance trained athletes: impact of thrombin and plasmin generation and catecholamine release
    M Mockel
    Department of Medicine, Humboldt University Berlin, Germany
    Int J Sports Med 22:337-43. 2001
    ..Mechanisms of platelet activation during exercise include phenomena other than plasmatic hemostatic factors and catecholamines...
  69. ncbi [Adjuvant therapy of pancreatic carcinoma]
    H Oettle
    Medizinische Klinik und Poliklinik m S Hämatologie und Onkologie, Medizinische Fakultat der Humboldt Universitat zu Berlin
    Praxis (Bern 1994) 89:2017-25. 2000
    ..In a multicenter German trial the benefit of gemcitabene as weekly monotherapy for 6 months is investigated. The treatment starts soon after resection due to low toxicity and good patient compliance...
  70. ncbi Epstein-Barr viral load in whole blood of adults with posttransplant lymphoproliferative disorder after solid organ transplantation does not correlate with clinical course
    Stephan Oertel
    Department of Hematology and Oncology, , Campus Virchow Klinikum, Augustenburger Platz 1, 13353, Berlin, Germany
    Ann Hematol 85:478-84. 2006
    ..We conclude that in adult patients with PTLD, EBV load does not correlate with treatment response and is not suitable as a predictive marker for PTLD relapse...
  71. ncbi Elevated reticulocyte count--a clue to the diagnosis of haemolytic-uraemic syndrome (HUS) associated with gemcitabine therapy for metastatic duodenal papillary carcinoma: a case report
    S Serke
    Department of Haematology Oncology, Charite, Campus Virchow Klinikum, , Berlin, Germany
    Br J Cancer 79:1519-21. 1999
    ..Re-exposure to gemcitabine 6 months after the episode of HUS instituted for progressive carcinoma, thus far has not caused another episode of HUS...
  72. ncbi Squamous cutaneous epithelial cell carcinoma in two CML patients with progressive disease under imatinib treatment
    Gökben Baskaynak
    Medizinische Klinik mit Schwerpunkt Hämatologie und Onkologie, Campus Virchow, Charite, Humboldt Universitat Berlin, Germany
    Eur J Haematol 70:231-4. 2003
    ..The role of chemotherapy, chronic sun exposure and of possible additional risk factors such as human papillomavirus infection is discussed...
  73. ncbi Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma
    H Oettle
    Charite Campus Virchow Klinikum, Medizinische Fakultat der Humboldt Universitat zu Berlin, Medizinische Klinik und Poliklinik mS Hämatologie und Onkologie, Berlin, Germany
    Anticancer Drugs 11:635-8. 2000
    ..This opens up an additional therapeutic option for a selected patient group with a poor prognosis so far...
  74. ncbi Continuation of regional chemotherapy of hepatic neoplasms despite occlusion of the hepatic artery-report of four cases
    Bert Hildebrandt
    Medical Clinic for Hematology and Oncology, Campus Virchow Clinic, Charite University Hospital, 13344 Berlin, Germany
    Anticancer Drugs 13:663-9. 2002
    ..Continuation of regional chemotherapy despite hepatic arterial occlusion preserved control of intrahepatic tumor manifestations in patients who previously responded to regular HAI...
  75. ncbi Thrombin activity throughout the acute phase of acute ST-elevation myocardial infarction and the relation to outcome
    Natalie Viviane Ulrich-Möckel
    Department of Cardiology, Charite Universitatsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany
    Biomarkers 14:311-6. 2009
    ..Data of thrombin and plasmin activity in the early course of STEMI and the relation to outcome are scarce...
  76. ncbi Whole body hyperthermia induces apoptosis in subpopulations of blood lymphocytes
    Annette Dieing
    Medical Clinic, Department of Hematology and Oncology, Charite Medical School, Humboldt University, Campus Mitte, Berlin, Germany
    Immunobiology 207:265-73. 2003
    ..Our results suggest, that apoptosis is one reason for the previously described decrease of T-cells during WBH and of NK-cells after WBH, and that the hyperthermia-related apoptosis-inducing mechanism is different in T-cells and NK-cells...
  77. ncbi First-line chemotherapy with weekly paclitaxel and carboplatin for advanced ovarian cancer: a phase I study
    Jalid Sehouli
    Department of Gynecology and Obstetrics, Charité Virchow University Hospital, Augustenberger Platz 1, 13353 Berlin, Germany
    Gynecol Oncol 85:321-6. 2002
    ..A multicenter, phase-I study was conducted to investigate the maximum tolerated dose of a weekly combination regimen...
  78. ncbi [Therapeutic modulation of coagulation in sepsis]
    A Loew
    , Medizinische Klinik und Poliklinik, Augustenburger Platz 1, 13353 Berlin
    Hamostaseologie 25:191-9. 2005
    ....
  79. ncbi [Acquired coagulopathies]
    H Riess
    Medizinische Klinik mit Schwerpunkt Hämatologie und Onkologie, Campus Virchow Klinikum, Universitatsklinikum Charite, Berlin
    Hamostaseologie 28:348-57. 2008
    ..Within the last years the role of therapeutic modulation of haemostasis to reduce mortality was successfully studied for the first time in the frame of randomized placebo-controlled phase III studies...
  80. ncbi Antiangiogenic strategies in pancreatic cancer
    H Riess
    Charite Universitatsmedizin Berlin, Campus Virchow Klinikum, Medizinische Klinik mit Schwerpunkt Hämatologie und Onkologie, Germany
    Recent Results Cancer Res 177:123-9. 2008
    ..Further investigations that will take into account the heterogeneity of pancreatic cancer are warranted using these or other antiangiogenic active substances...
  81. ncbi Pancreatic cancer: step by step forward
    H Riess
    , Campus Virchow-Klinikum, , Berlin, Germany
    Recent Results Cancer Res 177:1-2. 2008
  82. ncbi [Malpractice in determination of INR value in ambulatory care]
    A Loew
    , Campus Virchow Klinikum, , Augustenburger Platz 1, 13353 Berlin
    Internist (Berl) 43:1602-3. 2002
  83. ncbi Antiviral treatment of Epstein-Barr virus-associated lymphoproliferations
    Stephan H Oertel
    , , , Germany
    Recent Results Cancer Res 159:89-95. 2002
    ..These clinical experiences demonstrate the efficacy of antiviral treatment in EBV-associated lymphoproliferations...
  84. ncbi Comparison of six-month outcome of patients initially treated for acute deep vein thrombosis with a low molecular weight heparin Certoparin at a fixed, body-weight-independent dosage or unfractionated heparin
    Job Harenberg
    IV Dept of Medicine, University Hospital, Mannheim, Ruprecht Karls University Heidelberg, Mannheim, Germany
    Haematologica 88:1157-62. 2003
    ..We investigated whether these findings hold for a particular LMWH by pooling the results of two independent studies...
  85. ncbi 5-fluorouracil, folinic acid and oxaliplatin administered via hepatic arterial infusion as regional second-line therapy for advanced colorectal cancer
    Lars Meyer
    Oncology 64:473-4. 2003
  86. ncbi Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial
    Jean Francois Dhainaut
    Department of Intensive Care, Cochin Hospital AP HP, Cochin Institute, Cochin Port Royal Medical School, Paris V University, 27 rue due Faubourg Saint Jacques, 75679, Paris Cedex 14, France
    Intensive Care Med 29:894-903. 2003
    ..We report study's data on efficacy and safety in patients with multiple-organ dysfunction...
  87. ncbi Hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinosis
    Bert Hildebrandt
    J Clin Oncol 22:1527-9; author reply 1529. 2004
  88. ncbi Dynamic expression profile of p21WAF1/CIP1 and Ki-67 predicts survival in rectal carcinoma treated with preoperative radiochemotherapy
    Beate Rau
    Charite Medical School, Campus Berlin Buch, Humboldt University, Department of Surgery and Surgical Oncology, Robert Roessle Klinik, Lindenberger Weg 80, 13125 Berlin, Germany
    J Clin Oncol 21:3391-401. 2003
    ..The focus of this study was on the dynamics of these genetic markers in a longitudinal study-that is, before and after radiochemotherapy...
  89. ncbi Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study
    Cornelis J A Punt
    Department of Medical Oncology, University Medical Center St Radboud, PO Box 9101, 6500 HB Nijmegen, Netherlands
    Lancet 360:671-7. 2002
    ..We did a randomised trial in 27 countries to determine the effect of adding edrecolomab to the combination of fluorouracil and folinic acid in these patients...
  90. ncbi Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution
    Sylvain Choquet
    Department of Hematology, Hopital Pitie Salpetriere, Paris, France
    Ann Hematol 86:599-607. 2007
    ..Thus, prognostic indices can be useful tools for prediction of treatment outcome and for the development of risk-adapted treatment strategies in patients with PTLD and may also provide the basis for interstudy comparisons...
  91. ncbi Hypersensitivity reactions to oxaliplatin: cross-reactivity to carboplatin and the introduction of a desensitization schedule
    Lars Meyer
    J Clin Oncol 20:1146-7. 2002
  92. ncbi Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis
    Jean Francois Dhainaut
    Service de Reanimation Medicale, Centre Hospitalo Universitaire Cochin Port Royal, AP HP, Paris V University, Paris, France
    Thromb Haemost 90:642-53. 2003
    ..These latter two effects may occur at the local or cellular level. The systemic biomarkers reported here might not be the most appropriate approach to demonstrate these potential effects of drotrecogin alfa (activated)...
  93. ncbi Immunosurveillance, immunodeficiency and lymphoproliferations
    Stephan H Oertel
    , , , Germany
    Recent Results Cancer Res 159:1-8. 2002
    ..The occurrence of IALD demonstrates the importance of competent immunosurveillance in the development of lymphoid neoplasias, which may have therapeutic relevance too...
  94. ncbi Impact of cardiac surgery using cardiopulmonary bypass on course of chronic lymphatic leukemia: a case-control study
    Evgenij V Potapov
    Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Germany
    Ann Thorac Surg 74:384-9. 2002
    ..The number of older patients undergoing operations with cardiopulmonary bypass (CPB) is increasing. The aim of the present study was to evaluate the impact of cardiac surgery using CPB on the long-term course of CLL...
  95. ncbi [Hemostasis--an finely regulated protective mechanism? Pathophysiology of venous thromboembolism]
    Hanno Riess
    Medizinische Klinik mit Schwerpunkt Hämatologie und Onkologie, Charite, Campus Virchow Klinikum Augustenburger Platz 1, D 13353 Berlin
    Pharm Unserer Zeit 33:166-71. 2004